Publication details
Pacientka s chronickou myeloidní leukemií s rezistencí a/nebo nesnášenlivostí léčby třemi tyrosinkinázovými inhibitory
| Title in English | The patient with chronic myeloid leukemia, resistant and/or intolerant to three tyrosine kinase inhibitors |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | chronic myeloid leukemia; tyrosine kinase inhibitors; imatinib; dasatinib; nilotinib; ponatinib; T315I mutation; resistence; intolerance |
| Description | Treatment with tyrosine kinase inhibitors (TKI) dramatically improved prognosis of the patients with chronic myeloid leukemia (CML). Currently, three TKI are recommended and approved for the first line therapy: imatinib, dasatinib, and nilotinib. In case of resistance and/or intolerance to first line agents, two more drugs are approved, bosutinib and ponatinib. Ponatinib is the only agent able to inhibit multi-resistant mutation T315I. Neither ponatinib nor bosutinib are standardly reimbursed by the insurance companies in the Czechia, however they can be requested and finally reimbursed by a special tool, § 16 of the Low on Public Insurance. Presented case report describes successful therapy with ponatinib in CML patient resistant and/or intolerant to previous treatment with all currently available TKI in our country, imatinib, nilotinib and dasatinib. |